Drug intelligence / Profile preview

CBX-663

Development stage: Phase 1
Lead developer: Crossbow Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CBX-663 is a T-cell engager therapeutic developed by Crossbow Therapeutics. It targets telomerase reverse transcriptase (TERT), a protein expressed in up to 95% of cancers, making it a potential treatment for a wide range of solid tumors and hematologic malignancies[1][5][10].

Targets

CD3 (T-cell surface glycoprotein CD3)TERT540/HLA-A*02:01 (Telomerase reverse transcriptase peptide 540-548 presented by Human leukocyte antigen A*02:01)

Beyond the preview

Go deeper on CBX-663.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBX-663.

Explore the full profile